In a study involving 75 patients with clinical stage II–IV KRAS-mutant NSCLC, KRAS G12C mutation was identified as a predictive biomarker for better survival benefits from first-line chemotherapy in patients with advanced NSCLC with KRAS mutations (Lei et al., 2020). Here, KRAS is linked to non-small cell lung carcinoma.